GB0722203D0 - Use of CRTH2 antagonist compounds - Google Patents
Use of CRTH2 antagonist compoundsInfo
- Publication number
- GB0722203D0 GB0722203D0 GBGB0722203.7A GB0722203A GB0722203D0 GB 0722203 D0 GB0722203 D0 GB 0722203D0 GB 0722203 A GB0722203 A GB 0722203A GB 0722203 D0 GB0722203 D0 GB 0722203D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- antagonist compounds
- crth2 antagonist
- crth2
- compounds
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0722203.7A GB0722203D0 (en) | 2007-11-13 | 2007-11-13 | Use of CRTH2 antagonist compounds |
PCT/GB2008/003824 WO2009063202A2 (en) | 2007-11-13 | 2008-11-13 | Use of crth2 antagonist compounds |
ES08851028T ES2353055T1 (en) | 2007-11-13 | 2008-11-13 | USE OF CRTH2 ANTAGONIST COMPOUNDS. |
JP2010532660A JP2011503045A (en) | 2007-11-13 | 2008-11-13 | Use of CRTH2 antagonistic compounds |
EP08851028A EP2219645A2 (en) | 2007-11-13 | 2008-11-13 | Use of crth2 antagonist compounds |
DE08851028T DE08851028T1 (en) | 2007-11-13 | 2008-11-13 | USE OF CRTH2 ANTAGONIST COMPOUNDS |
US12/779,638 US20110124683A1 (en) | 2007-11-13 | 2010-05-13 | Use of CRTH2 Antagonist Compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0722203.7A GB0722203D0 (en) | 2007-11-13 | 2007-11-13 | Use of CRTH2 antagonist compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0722203D0 true GB0722203D0 (en) | 2007-12-19 |
Family
ID=38858584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0722203.7A Ceased GB0722203D0 (en) | 2007-11-13 | 2007-11-13 | Use of CRTH2 antagonist compounds |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2219645A2 (en) |
JP (1) | JP2011503045A (en) |
DE (1) | DE08851028T1 (en) |
ES (1) | ES2353055T1 (en) |
GB (1) | GB0722203D0 (en) |
WO (1) | WO2009063202A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2327693T3 (en) * | 2007-12-14 | 2012-08-13 | Pulmagen Therapeutics Asthma Ltd | Indoles and their therapeutic use |
US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
DK2250161T3 (en) * | 2008-01-18 | 2014-01-27 | Atopix Therapeutics Ltd | Compounds with CRTH2 antagonist activity |
JP2011509991A (en) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Compound having CRTH2 antagonist activity |
US20100022613A1 (en) * | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
CN101952244B (en) | 2008-02-01 | 2014-11-05 | 潘米拉制药公司 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
US8501959B2 (en) | 2008-06-24 | 2013-08-06 | Panmira Pharmaceuticals, Llc | Cycloalkane[B]indole antagonists of prostaglandin D2 receptors |
US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
SG178109A1 (en) | 2009-07-31 | 2012-03-29 | Panmira Pharmaceuticals Llc | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
SG10201404662YA (en) | 2009-08-05 | 2014-10-30 | Panmira Pharmaceuticals Llc | Dp2 antagonist and uses thereof |
JP2013516475A (en) | 2010-01-06 | 2013-05-13 | アミラ ファーマシューティカルズ,インク. | DP2 antagonists and uses thereof |
WO2011117798A1 (en) | 2010-03-22 | 2011-09-29 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
RU2589709C2 (en) * | 2010-12-23 | 2016-07-10 | Мерк Шарп Энд Домэ Корп. | Quinoxalines and azaquinoxalines as crth2 receptor modulators |
GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
MX338516B (en) | 2011-04-14 | 2016-04-20 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators. |
CN103086943B (en) * | 2011-11-04 | 2015-04-15 | 山东亨利医药科技有限责任公司 | Indoles derivative functioning as CRTH2 receptor antagonist |
MA39750B1 (en) | 2014-03-17 | 2018-12-31 | Idorsia Pharmaceuticals Ltd | Derivatives of aza-indol-acetic acid and their use as modulators of prostaglandin receptors d2 |
TW201620909A (en) | 2014-03-18 | 2016-06-16 | 艾克泰聯製藥有限公司 | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
EP3350179B1 (en) | 2015-09-15 | 2021-01-13 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
WO2017104728A1 (en) * | 2015-12-16 | 2017-06-22 | 国立大学法人東京大学 | Medicine for treating food allergy |
US10800765B2 (en) * | 2016-07-21 | 2020-10-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Indole derivative used as CRTH2 inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
GB0605743D0 (en) * | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
NZ574375A (en) * | 2006-07-22 | 2011-06-30 | Oxagen Ltd | 2-(5-fluoro-2-methyI-3-(2-(phenylsulfonyl)benzyl)-1H-indol-1-yl) acetic acid derivatives having CRTH2 antagonist activity |
-
2007
- 2007-11-13 GB GBGB0722203.7A patent/GB0722203D0/en not_active Ceased
-
2008
- 2008-11-13 ES ES08851028T patent/ES2353055T1/en active Pending
- 2008-11-13 DE DE08851028T patent/DE08851028T1/en active Pending
- 2008-11-13 EP EP08851028A patent/EP2219645A2/en not_active Ceased
- 2008-11-13 WO PCT/GB2008/003824 patent/WO2009063202A2/en active Application Filing
- 2008-11-13 JP JP2010532660A patent/JP2011503045A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2009063202A2 (en) | 2009-05-22 |
WO2009063202A3 (en) | 2009-08-27 |
JP2011503045A (en) | 2011-01-27 |
ES2353055T1 (en) | 2011-02-25 |
EP2219645A2 (en) | 2010-08-25 |
DE08851028T1 (en) | 2011-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0722216D0 (en) | Use of crth2 antagonist compounds | |
GB0722203D0 (en) | Use of CRTH2 antagonist compounds | |
HK1145175A1 (en) | Compounds having crth2 antagonist activity | |
IL196640A0 (en) | Compounds having crth2 antagonist activity | |
HK1172326A1 (en) | Compounds and compositions and methods of use | |
HK1147674A1 (en) | Heterocyclic compounds as crth2 receptor antagonists crth2 | |
IL202679A0 (en) | Particulates of a crth2 antagonist | |
AP2008004406A0 (en) | Methods of managing timberland | |
PL2328545T3 (en) | Use of glucosylglycerol | |
HK1160925A1 (en) | Use of athepsin | |
AP2784A (en) | Methods of managing timberland | |
HK1137187A1 (en) | Use of tocopherol | |
ZA200806508B (en) | Salt of CD80 Antagonist | |
ZA200900393B (en) | Compounds having CRTH2 antagonist activity | |
PL2237782T3 (en) | Use of tetrahydropyrimidines | |
GB0801674D0 (en) | Compounds having CRTH2 antagonist activity | |
GB201114396D0 (en) | Location of basesation | |
GB0801672D0 (en) | Compounds having crth2 antagonist activity | |
GB0801671D0 (en) | Compounds having crth2 antagonist activity | |
GB0820526D0 (en) | Compounds having crth2 antagonist activity | |
GB0801131D0 (en) | Compounds having CRTH2 antagonist activity | |
GB0800874D0 (en) | Compounds having CRTH2 antagonist activity | |
GB0801132D0 (en) | Compounds having CRTH2 antagonist activity | |
GB0624176D0 (en) | Compounds having CRTH2 antagonist activity | |
PL383759A1 (en) | New application of undecane-2-ol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |